A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Paliperidone Palmitate Evaluating Time to Relapse in Subjects With Schizoaffective Disorder.
Phase of Trial: Phase III
Latest Information Update: 01 Apr 2017
At a glance
- Drugs Paliperidone (Primary)
- Indications Schizoaffective disorder
- Focus Registrational; Therapeutic Use
- Sponsors Janssen Pharmaceuticals; Janssen-Cilag
- 17 Jun 2016 Results published in the Journal of Clinical Psychopharmacology
- 20 Oct 2014 Results presented at the 27th Annual Congress of the European College of Neuropsychopharmacology.
- 06 May 2014 Primary endpoint 'Time-to-relapse' has been met, according to a Janssen Pharmaceuticals media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History